Navigation Links
Nephros Reports Third Quarter 2013 Financial Results and Completes Bridge Financing
Date:11/14/2013

RIVER EDGE, N.J., Nov. 14, 2013 /PRNewswire/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today financial results for the three and nine months ended September 30th 2013 and that the company entered into a bridge loan and security agreement with Lambda Investors LLC, an affiliate of Wexford Capital LP and the company's largest shareholder.

Financial Performance for the Third Quarter Ended September 30, 2013
Total net revenues for the three months ended September 30, 2013 were approximately $418,000 compared to approximately $604,000 for the three months ended September 30, 2012.  Total net revenues decreased by approximately $186,000, or 31%.  Overall, the key business segments of dialysis water and hospital water revenue increased by approximately $45,000 for the three months ended September 30, 2013.  There were no Military sales in the three months ended September 30, 2013 as compared with $114,000 of Military sales in the same period in 2012, in addition to which approximately $127,000 of anticipated sales credits are recorded to reflect the impact of a voluntary product recall of point of use filters (POU) announced on October 30, 2013. The overall product revenue decrease of $196,000, or 45%, is offset partially by an increase of approximately $10,000 as a result of increased licensing revenue related to the Bellco license agreement.

Total operating expenses for the quarter ended September 30, 2013 were $837,000 compared with $1,266,000 for the quarter ended September 30, 2012. The decrease was primarily driven by decreases in legal, accounting and professional services fees as well as personnel costs during the quarter ended September 30, 2013 compared to the quarter ended September
'/>"/>

SOURCE Nephros, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nephros Appoints John C. Houghton as President and Chief Executive Officer
2. Nephros Receives 510(k) Clearance for Hemodiafiltration System
3. Nephros Reports First Quarter 2012 Financial Results
4. Nephros Reports Second Quarter 2012 Financial Results
5. Nephros Reports Third Quarter 2012 Financial Results
6. Nephros and Chem-Aqua Announce Distribution Agreement
7. Nephros Completes Bridge Financing
8. Nephros Reports 2012 Fourth Quarter and Full Year Financial Results
9. Nephros Announces Rights Offering and Temporary Reduction in Exercise Price for March 2011 Warrants
10. Nephros Reports First Quarter 2013 Financial Results
11. Nephros Announces Completion of Rights Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- Decision Resources Group finds that the laparoscopic device market ... increase to a value of over $4.3 billion by ... the large direct energy device market. In particular, premium-priced ... to the advantages they offer and as new products ... Resources Group,s coverage of the U.S. laparoscopic device market: ...
(Date:12/19/2014)... Kan. , Dec. 18, 2014   ... ), a biopharmaceutical company focused on the licensing, ... animals, today announced positive results from its pivotal ... drug for treating pain in dogs with osteoarthritis. ... in pain assessment scores that were statistically significant ...
(Date:12/17/2014)... , December 17, 2014 Revenue and ... expenditure on research and development In the past ... revenue by two percent to EUR 4.287 billion (last year: ... by 14 percent to EUR 360 million. "Overall, 2013/14 was ... Michael Kaschke , President and CEO of Carl Zeiss ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5ZEISS Asserts its Position in Difficult Environment 2
... with Leading Researchers having Clinical Experience with Antimicrobials ... April 22 NovaBay Pharmaceuticals, Inc. (NYSE Amex: ... developing first-in-class, potent, well-tolerated products to treat and ... chance of developing drug resistance, today announced an ...
... initiation of clinical studies; Data to be presented ... Drug discovery and development company Esperance Pharmaceuticals ... program that support the initiation of clinical ... from the Company,s Cationic Lytic Peptide (CLYP(TM)) platform ...
Cached Medicine Technology:NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 2NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 3NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds 4First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept 2First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept 3
(Date:12/20/2014)... MissyDress, a distinguished special dress supplier, has just ... has drastically cut prices to all its prom dresses ... 30, 2015. Many of the hottest styles are sold ... dresses, and more. , A spokesman for MissyDress says, ... A-line princess prom dresses or sweetheart chiffon prom dresses, ...
(Date:12/20/2014)... Dress company LunaDress has recently announced its ... Sale, offering big discounts on all of its special occasion ... to own a perfect wedding gown. If you have no ... come to LunaDress. Many different wedding dress styles and our ... now and enjoy the current special offer, up to 80% ...
(Date:12/20/2014)... holidays can be anything but joyous for people with ... and other allergy triggers. "The dust from the ... away in dank basements or dusty attics is triggering ... Shah, an affiliate faculty member at Loyola University Chicago ... Shah, who is also an allergist at Gottlieb ...
(Date:12/20/2014)... 2014 Angeldress.co.uk, the distinguished wedding dress ... worldwide dress fans. The company has recently updated its ... For the holiday season, Angeldress Blog has ... apparel. , Angeldress.co.uk prides itself in offering a huge ... service. All the company’s outfits are very carefully selected ...
(Date:12/20/2014)... York, NY (PRWEB) December 20, 2014 The ... has caused quite a stir, not only in Hollywood, but ... on December 18th , the ripples of that attack are ... executives’ very jobs at risk. But they are not ... correspondences exposed could be in for some embarrassing times ahead, ...
Breaking Medicine News(10 mins):Health News:MissyDress: The Prices of Prom Dresses Just Reduced 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:Holiday Trimmings Can Trigger Allergies 2Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 2Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 3Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 4Health News:Sony Pictures Hack Perfect Example of the Reach a Single Cyber Attack Can Have 5
... 10 Breckenridge announced today,that it has entered into ... ANDA products. The first project is currently filed and,pending ... with the FDA for,the second product in the 3rd ... will be supplied by Orit Laboratories, and will be ...
... the University of Pennsylvania School of Medicine have discovered ... of an important heart muscle protein called actin. Whats ... the pumping unit of the heart. The findings appear ... was known about Lmod when we began this study, ...
... Seven Members, DALLAS, April 10, Crdentia ... company, today said,that its Board of Directors has ... Board of Directors, effective immediately. This announcement,expands the ... John Kaiser, Crdentia,s President and Chief Executive Officer, ...
... brains of infants distinguish differences in sounds and it ... children start to speak, sparing them the difficulties that ... by Professor of Neuroscience April Benasich and her Infancy ... new and exciting clues about how infant brains begin ...
... clinical trials could start in several years, study says , , ... inhibits the formation of scar tissue at the site of ... regenerate has been developed by researchers at Northwestern University in ... ability to regrow after a spinal injury, but they,re blocked ...
... 10, 2008) Carotid artery stenting is an ... eligible for surgery, according to a long-term study published ... artery disease, which involves clogging of the arteries in ... a significant risk factor for stroke, making these study ...
Cached Medicine News:Health News:Penn researchers discover 'modus operandi' of heart muscle protein 2Health News:Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors 2Health News:Crdentia Announces Appointments of David Jenkins and Raymond Dunn to Board of Directors 3Health News:Impairments in language development can be detected in infants as young as 3 months 2Health News:Impairments in language development can be detected in infants as young as 3 months 3Health News:Gel Enables Severed Spinal Cord Fibers to Regrow 2Health News:SAPPHIRE trial shows long-term benefit of carotid stenting as alternative to surgery 2Health News:SAPPHIRE trial shows long-term benefit of carotid stenting as alternative to surgery 3
... Anchor is available in 3.5 mm, 5 mm ... minor diameter and a cancellous screw thread design ... laser mark on the distal part of the ... eyelets. When the anchor is inserted, the vertical ...
... - As easy to use as its ... demanding medical justification of therapeutic procedures. For ... tract symptoms (LUTS), that requires urodynamics. ... becoming routine in the office environment, with ...
... The FASTak II Suture Anchor is a ... that is inserted directly into bone without predrilling ... the Tear Drop Handle, Keyless Chuck or the ... and SLAP repairs as well as other small ...
... offer the best bioabsorbable solution for soft ... thread design and small core diameter provide ... braided suture loop is molded into the ... eyelet that virtually eliminates abrasion to attached ...
Medicine Products: